Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).

Guenter AuerswaldClaudia Djambas KhayatOleksandra StasyshynGenadi IosavaIrina RomashevskayaMarta Julia LópezWilfried SeifertTobias Rogosch

Published in: Journal of blood medicine (2020)

This study provides evidence for use of Formulation V to treat and prevent bleeding in pediatric patients with severe VWD, and led to the European approval of Formulation V in children.

Keyphrases

drug delivery
atrial fibrillation
early onset